Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04790773 · ClinicalTrials.gov registry record · NA
Alexa, What is Eliquis and Xarelto?
A NA study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT04790773: Clinical Trial NA study, sponsored by Cedars-Sinai Medical Center.
NCT04790773 is a NA study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04790773, a NA study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.
Primary Outcome
Effectiveness of Alexa based education by assessing understanding of Eliquis and Xarelto pre and post Alexa education
Interventions
- OTHER Amazon Alexa based voice recording patient education
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2021-10-31 |
| Phase | NA |
Why NCT04790773 stopped before completion
NCT04790773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Amazon Alexa based voice recording patient education is the first listed.
NCT04790773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04790773 about?
NCT04790773 is a clinical study titled "Alexa, What is Eliquis and Xarelto?". The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.
What is the current status of trial NCT04790773?
This trial is currently terminated. It is a NA study. The enrollment target is 36 participants. The study started on 2021-05-21. Estimated completion is 2021-10-31.
What interventions are being tested in trial NCT04790773?
The interventions under investigation include: Amazon Alexa based voice recording patient education (OTHER).
Who is sponsoring clinical trial NCT04790773?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04790773's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI